Search Results

You are looking at 1 - 10 of 75 items for :

  • "Beta blockers" x
  • All content x
Clear All

Resolution of racemic metoprolol, propranolol, carvedilol, bisoprolol, salbutamol, and labetalol, commonly used β-blockers, into their enantiomers has been achieved by TLC on silica gel plates impregnated with optically pure L -Glu and L -Asp. Acetonitrile-methanol-water-dichloromethane and acetonitrile-methanol-water-glacial acetic acid mobile phases in different proportions enabled successful separation. The spots were detected with iodine vapor. The detection limits were 0.23, 0.1, 0.27, 0.25, 0.2, and 0.2 μg for each enantiomer of metoprolol, propranolol, carvedilol, bisoprolol, salbutamol, and labetalol, respectively.

Restricted access

A simple and rapid method has been established for indirect separation of the enantiomers of (R,S)-metoprolol and (R,S)-carvedilol by reversed-phase TLC. Beta blockers derivatized with 1-fluoro-2,4-dinitrophenyl-5-l-alanine amide (Marfey’s reagent, FDNP-l-Ala-NH2) and its six structural variants (FDNP-l-Phe-NH2, FDNP-l-Val-NH2, FDNP-l-Pro-NH2, FDNP-l-Leu-NH2, FDNP-l-Met-NH2, and FDNP-d-Phg-NH2) were spotted on precoated plates. (R,S)- Metoprolol and (R,S)-carvedilol were isolated from pharmaceutical dosage forms and purified. The diastereomers were separated most effectively by use of mobile phases containing acetonitrile and triethylamine-phosphate buffer (50 mM, pH 5.5). The results obtained by use of Marfey’s reagent were compared with those obtained by use of the other variants. The effects of buffer concentration, pH, and concentration of organic modifier were studied.

Restricted access

Resolution of the enantiomers of racemic atenolol, metoprolol, propranolol, and labetalol, commonly used β-blockers, has been achieved by TLC on silica gel plates using vancomycin as chiral impregnating reagent or as chiral mobile phase additive. With vancomycin as impregnating agent, successful resolution of the enantiomers of atenolol, metoprolol, propranolol, and labetalol was achieved by use of the mobile phases acetonitrile-methanol-water-dichloromethane 7:1:1:1 ( v/v ), acetonitrile-methanol-water 6:1:1 ( v/v ), acetonitrile-methanol-water-dichloromethane-glacial acetic acid 7:1:1:1:0.5 ( v/v ), and acetonitrile-methanol-water 15:1:1 ( v/v ), respectively. With vancomycin as mobile phase additive, successful resolution of the enantiomers of metoprolol, propranolol, and labetalol was achieved by use of the mobile phases acetonitrile-methanol-0.56 mM aqueous vancomycin (pH 5.5) 6:1:1 ( v/v ), acetonitrile-methanol-0.56 mM aqueous vancomycin (pH 5.5) 15:1:2 ( v/v ), and acetonitrile-methanol-0.56 mM aqueous vancomycin (pH 5.5)-dichloromethane 9:1:1.5:1 ( v/v ), respectively. Spots were detected by use of iodine vapor. The detection limits were 1.3, 1.2, 1.5, and 1.4 μg for each enantiomer of atenolol, metoprolol, propranolol, and labetalol, respectively.

Restricted access

A chromatographic-densitometric method has been established for identification and quantitation of selected beta-adrenergic-blocking agents in pharmaceutical preparations. Retention factors, R F , and characteristic absorption spectra of 11 drugs chromatographed on silica gel 60 F 254 HPTLC plates with six mobile phases were used for identification. Quantitation and validation of the method was performed for atenolol, acebutolol, propranolol, and bisoprolol using chloroform-methanol-ammonia, 15 + 7 + 0.2 ( v/v ), as mobile phase. UV densitometric measurements were performed at the wavelength of maximum absorption. Pharmaceutical preparations used in medicine and from a variety of manufacturers were analyzed and the method shown to be sufficiently sensitive for analysis of these samples. The limits of detection and determination ranged from 30 to 400 ng and recovery was from 97.14 to 102.18%. The precision of the method, described by the equation y = x mean ± 2 S , is good and the range of linearity is wide — from 0.020 to 0.250% for individual constituents.

Restricted access

Opie L, Yusuf S. Beta-blocking agents. In: Opie LH, Gersh B. (eds.) Drugs for the heart, 6th ed. WB Saunders Company, Philadelphia, Pensylvania, 2005; pp. 1–32. 5 Morgan T

Restricted access

. Linde, K., Rossnagel, K.: Propranolol for migraine prophylaxis. Cochrane Database Syst. Rev., 2004, (2), CD003225. Bangalore, S., Sawhney, S., Messerli, F. H.: Relation of beta-blocker-induced heart rate lowering

Restricted access

.: Differing beta-blocking effects of carvedilol and metoprolol. Europ. J. Heart Failure 3, 343-349 (2001) Differing beta-blocking effects of carvedilol and metoprolol Europ. J. Heart Failure

Restricted access

.: On what criteria should we choose the beta-blocker? [Mi alapján válasszunk béta-blokkolót?] Card. Hung., 2012, 42 (5), 317–321. [Hungarian] 4 Dézsi, C. A

Open access

: 2143. 8 Schuman JS. Effects of systemic beta-blocker therapy on the efficacy and safety of topical brimonidine and timolol. Brimonidine Study Groups 1 and 2. Ophthalmology 2000

Restricted access

, 2010, 20 (5), 305–307. [Hungarian] Dézsi, C. A.: On what criteria should we choose the beta-blocker? [Mi alapján válasszunk béta-blokkolót?] Cardiologia Hungarica, 2012, 42 (5), 317–321. [Hungarian

Open access